BioNTech IPO
BioNTech is a German biotechnology company developing individualized therapies for cancer and other serious diseases using mRNA technology. The company became globally known for partnering with Pfizer to develop one of the first COVID-19 vaccines approved for emergency use.
What We Know
BioNTech went public on NASDAQ in October 2019 under the ticker BNTX, raising approximately $150 million in its IPO. The German company also trades on the Frankfurt Stock Exchange. BioNTech's stock price experienced massive growth during the COVID-19 pandemic due to the success of its Pfizer-partnered vaccine. The company continues to trade publicly and has expanded its mRNA platform beyond COVID-19 into cancer immunotherapy and other applications.
Frequently Asked Questions
Has BioNTech had an IPO?
Yes, BioNTech completed its IPO in October 2019 and trades publicly on NASDAQ under the ticker BNTX. The company also trades on European exchanges.
When is the BioNTech IPO date?
BioNTech already completed its IPO in October 2019. The company is currently publicly traded and does not need another IPO.
How can I buy BioNTech stock?
You can buy BioNTech stock through any brokerage account using the ticker symbol BNTX on NASDAQ. The stock is available to retail investors during regular market hours.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts